Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

Despite online claims, President Donald Trump’s executive orders did not include removing Medicare’s $35 monthly out-of-pocket price cap, which is set by law.

As the next round of Medicare drug pricing negotiations get underway, experts predict President Trump may seek to weaken the program.

Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...